PDS Biotechnology Corp — Director's Dealing 2016

Dec 2, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-12-01

Reporting Person: Leuthner Brian A (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-01	Common Stock	S	7500	$11.60	Disposed	252979	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	275479	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $11.11 to $12.35 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.